Berlin, Germany
Berlin, Germany
SEARCH FILTERS
Time filter
Source Type

News Article | December 8, 2016
Site: www.eurekalert.org

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) today announced the winners of the second round of an ideas competition in international research marketing. Awards will go to the Humboldt University of Berlin, Goethe University Frankfurt and the GFZ German Research Centre for Geosciences in Potsdam. The three institutions will each receive prize money of 100,000 euros to implement their research marketing actions. In addition, a special start-up prize was offered for the first time this year, designed for recipients who want to establish research marketing at their institutions. This special award, worth 75,000 euros, will go to the Technical University of Kaiserslautern. The prizes are funded from special funds of the German Federal Ministry of Education and Research (BMBF). The award ceremony will be held in Potsdam on 16 February 2017. This year 19 universities and research institutions took part in the competition. The ideas competition is designed to promote activities that enhance the visibility and attractiveness of German research abroad and attract highly qualified researchers, either to participate in collaborative projects with German researchers or to visit Germany for research purposes. "We believe that the role of international research marketing at higher education institutions is more important now than ever before and that universities must be supported in developing structures to enhance this area," said DFG Secretary General Dorothee Dzwonnek. "The competition for the best minds is getting more difficult worldwide. It is becoming increasingly important to boost Germany's visibility as an outstanding place of research in the global research system and to attract highly qualified researchers to Germany. For this reason, strategic international research marketing will become more and more significant for German research institutions," Dzwonnek continued. The winning ideas impressed the international selection panel, consisting of research managers and experts in internationalisation, communication and marketing, through their bold approaches and successful focus on individual institutional competence. The proposed activities were found to be very tangible and represent genuine partnerships between research and administration within the universities and research institutions, strongly anchored at the leadership level. In addition, the actions no longer merely focus on individual institutions, but on regions and their core research areas: The focus of the research marketing proposal submitted by the Humboldt University of Berlin is a journalist-in-residence programme. Together with the Technical University of Berlin, the Charité and the Einstein Foundation Berlin and with the support of the Wissenschaft im Dialog initiative and Berlin Partner für Wirtschaft und Technologie GmbH, talented young journalists from North and South America and Asia - regions where the Humboldt University has strategically developed its international network - will be invited to visit Berlin. They will have the opportunity to get to know Berlin as a hub of research, including its clusters of excellence and graduate schools, and report on their impressions back home. The idea presented by Goethe University Frankfurt is based on the university's core research area in ubiquitin and autophagy research (UBAUT), which came about through the Collaborative Research Centre "Molecular and Functional Characterisation of Selective Autophagy". The aim is to network UBAUT research in the Rhine-Main region with leading universities in the San Francisco Bay Area and the Greater Boston area. To this end, a fellowship programme will be established and a convention for German and US researchers will be organised on the US West Coast. The joint research marketing idea designed by the GFZ German Research Centre for Geosciences and the Geo.X network focuses on two regions: Russia and the Middle East. This clear regional focus is intended to help maintain bilateral dialogue through research and promote scientific collaboration in regions where little has been done to date in this area. The GFZ will organise summer schools and workshops specifically for early career researchers. Networking opportunities will also be offered through "Geoscience Days" at the German embassies in the chosen regions. The special start-up prize, offered for the first time in 2016, will go to the Technical University of Kaiserslautern. Through a proposal entitled Kaiserslautern Research Matching (KAREMA), the university is taking its first systematic steps in international research marketing. It intends to recruit international postdoctoral researchers in the following core research areas: optics and material sciences; mathematical modelling in the engineering sciences; and biology and biotechnology. In the jury's view, this project could provide inspiration for other smaller institutions. The International Research Marketing project is a joint initiative of the DFG, the Alexander von Humboldt Foundation (AvH), the German Academic Exchange Service (DAAD) and the Fraunhofer-Gesellschaft (FhG). These organisations promote Germany as a place to carry out research through the "Research in Germany" brand. The project is funded by the German Federal Ministry of Education and Research as part of the initiative "Promote innovation and Research in Germany". For more information about the DFG ideas competition "International Research Marketing", visit: http://www. (only available in German)


News Article | November 15, 2016
Site: www.prnewswire.co.uk

Cologne, Germany was the center of drug development partnering last week where 3,700 high level executives from the life science/drug development industry attended BIO-Europe® 2016 global life science partnering event, held November 7-9, 2016. BIO-Europe 2016 broke records for number of delegates and number of one-to-one partnering meetings which reached 20,833, an all-time high and up 9% from 2015. CEOs and decision makers from 1,982 companies and 63 countries discussed asset deals and strategic collaborations. There were 4,734 licensing opportunities on offer, 153 company presentations and 97 exhibitors. "The incredible success of BIO-Europe in Cologne is both a testament to the region's key central European location and its strong biopharma sector, as well as the increased need for partnering as a critical ingredient in successful strategic planning by companies spanning the drug development spectrum, " said Anna Chrisman, Group Managing Director, EBD Group. "This spectrum has grown to include early stage academia, startup biotech companies, innovators in cell and gene therapy and digital medicine, and many more, making BIO-Europe a fully integrated partnering event that has real relevance in the future of healthcare." A Startup Slam pitching competition took place during the course of the event, offering emerging entrepreneurs a chance to pitch their company to business development executives, venture capitalists and industry experts. The event, sponsored by Johnson & Johnson Innovation with support from Innovation Forum and BIO.NRW, was won by Jeremy Chrisp of EpiAxis Therapeutics Pty Ltd, a new startup company spun out from the University of Canberra in Australia. They aim to commercialize their novel approach to prevent the recurrence of metastasis, with an initial focus on breast cancer. Planning is already underway for BIO-Europe 2017 which will take place in Berlin, Germany, November 6-8, 2017 in partnership with Berlin Partner and Berlin-Brandenberg HealthCapital. As a leading hub for life sciences, the German capital region will welcome biotech experts from Europe and abroad. The region's biotech sector in particular has registered steady growth and high startup dynamism, with 90% of the 240 biotech cluster companies working in biomedicine. A strength of the region its unique research landscape, the close links between science and industry and the excellent infrastructure for clinical trials with more than 130 clinics, including Europe's largest university hospital, the Charité. "As a leading location for innovation in biotechnology and pharmaceuticals, we are delighted that BIO-Europe 2017 is returning to Berlin,"  said  Dr. Kai Uwe Bindseil, Cluster Manager for Healthcare Industries in Berlin-Brandenburg - HealthCapital. "Every day, over 240 biotech companies in the capital region are working on the development of new active substances and diagnostics-at BIO-Europe, we place this excellence at the forefront and are creating the foundation for new international cooperations." Early planning is now in place to bring BIO-Europe to Copenhagen, Denmark in 2018 in partnership with Invest in Skåne and Copenhagen Capacity. Copenhagen is an important biotech and life science location for a global audience. The region's life science cluster, Medicon Valley, spanning Eastern Denmark and Southern Sweden, is world leader within cancer, metabolic diseases, inflammation and brain/central nervous system diseases, and it is highly recognized for its strong patents and product pipeline as well as for the unique and successful collaboration between industry, academia and government. Watch video coverage from BIO-Europe and other key partnering events, including interviews with executives and thought leaders from the life science industry, on EBD Group's Insight, a premier news source for the biopharma industry, or by following the #BIOEurope event hashtag on Twitter. EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. EBD Group's conferences are run with the support of leading corporations and international trade associations and include: EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year. Tune into EBD Group's Insight for timely coverage of news that influences the business strategies of the life science industry. EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world. EBD Group has offices in the USA and Europe. For more information please visit http://www.ebdgroup.com.


News Article | November 21, 2016
Site: www.prnewswire.co.uk

La ville allemande de Cologne, où se sont retrouvés 3 700 hauts dirigeants du secteur des sciences de la vie/du développement de médicaments à l'occasion de la tenue, du 7 au 9 novembre 2016, de l'événement de partenariat en sciences de la vie BIO-Europe® 2016 au rayonnement international, a été le centre névralgique des partenariats favorables à la mise au point de médicaments. L'édition 2016 de BIO-Europe a battu des records en termes de participation de représentants et de réunions de partenariat. Il a en effet été dénombré 20 833 réunions de partenariat individuelles, un chiffre sans précédent, en hausse de 9 % par rapport à 2015. Des dirigeants et décideurs de 1 982 entreprises et 63 pays ont parlé collaborations stratégiques et « asset deals ». Au total, 4 734 offres d'octroi de licence, 153 présentations d'entreprises et 97 exposants ont été répertoriés. « L'incroyable succès de l'évènement BIO-Europe organisé à Cologne s'explique à la fois par l'emplacement stratégique de la ville au centre de l'Europe, la solidité de son secteur biopharmaceutique et le besoin accru de nouer des partenariats qu'ont les entreprises couvrant tout le spectre du développement de produits pour mener à bien avec succès leur plan stratégique », a déclaré Anna Chrisman, directrice générale du groupe EBD. « Ce spectre s'est élargi au point d'englober désormais les universités se consacrant aux premiers stades de la recherche de médicaments, les start-up spécialisées dans les biotechnologies, les innovateurs dans les domaines des thérapies cellulaire et génique et de la médecine numérique, pour ne citer qu'eux. Dans ce contexte, BIO-Europe est un évènement de partenariat totalement intégré qui a toute sa place dans le devenir du secteur de la santé. » Un concours de présentation des start-up en mode slam organisé lors de l'évènement a permis à de nouveaux entrepreneurs de pouvoir présenter leur entreprise à des responsables du développement, des capital-risqueurs et des spécialistes du secteur. Sponsorisé par Johnson & Johnson Innovation avec le soutien du Forum de l'innovation et de BIO.NRW, ce concours a été remporté par Jeremy Chrisp d'EpiAxis Therapeutics Pty Ltd, une nouvelle start-up qui a vu le jour à l'Université de Canberra en Australie. Son objectif ? Commercialiser sa nouvelle approche en matière de prévention des récidives du cancer en se focalisant dans un premier temps sur le cancer du sein. Les préparatifs de l'édition 2017 de BIO-Europe, qui se déroulera à Berlin en Allemagne du 6 au8 novembre 2017 en partenariat avec Berlin Partner et Berlin-Brandenburg HealthCapital, sont déjà en cours. Pôle de premier plan pour les sciences de la vie, la capitale allemande accueillera des spécialistes des biotechnologies venus d'Europe et d'autres pays. Le secteur des biotechnologies de la région a enregistré une croissance stable et connu un fort dynamisme à l'échelle des start-up. En effet, 90 % des 240 entreprises spécialisées dans les biotechnologies opèrent dans le domaine de la biomédecine. La région a l'avantage de bénéficier d'un environnement particulièrement propice à la recherche et de pouvoir s'appuyer sur les liens étroits qui existent entre les sciences et l'industrie ainsi que sur d'excellentes infrastructures pour la réalisation d'essais cliniques avec plus de 130 établissements de soins médicaux, parmi lesquels le plus grand hôpital universitaire d'Europe, la Charité. « Nous sommes ravis que l'édition 2017 de BIO-Europe revienne à Berlin, une ville au premier plan de l'innovation dans les biotechnologies et les produits pharmaceutiques, », a indiqué le Dr Kai Uwe Bindseil, responsable de l'activité cluster dédiée au secteur de la santé chez Berlin-Brandenburg - HealthCapital. « Chaque jour, plus de 240 entreprises spécialisées dans les biotechnologies implantées dans la région de la capitale travaillent à la mise au point de nouvelles substances actives et techniques de diagnostic ; BIO-Europe met cette excellence en exergue et jettent les bases de nouvelles coopérations internationales. » Les premiers préparatifs ont commencé pour organiser BIO-Europe à Copenhague au Danemark en 2018 en partenariat avec Invest in Skåne et Copenhagen Capacity. Copenhague est une ville importante dans le domaine des biotechnologies et des sciences de la vie aux yeux d'un public mondial. Le pôle régional spécialisé dans les sciences de la vie, Medicon Valley, qui couvre l'Est du Danemark et le Sud de la Suède, est le leader mondial pour le cancer, les maladies métaboliques, les maladies du système nerveux central/du cerveau et inflammatoires. Il est hautement reconnu pour son solide portefeuille de produits et de brevets, de même que pour sa collaboration fructueuse et originale entre l'industrie, les universités et l'État. Vous pouvez visionner des vidéos de différentes éditions de BIO-Europe et d'autres évènements de partenariat majeurs, comprenant des entretiens avec des dirigeants et des leaders d'opinion du secteur des sciences de la vie, sur Insight d'EBD Group, source d'information de premier plan pour le secteur biopharmaceutique, ou en suivant le hashtag #BIOEurope sur Twitter. Suivez BIO-Europe sur Twitter :  @EBDGroup (hashtag : #BioEurope). EBD Group est la principale société de partenariat dans le secteur mondial des sciences de la vie. Depuis 1993, des sociétés biotechnologiques, pharmaceutiques et du secteur des dispositifs médicaux tirent parti des technologies, des services et des conférences de partenariat d'EBD Group pour identifier des possibilités commerciales et développer des relations stratégiques essentielles à leur succès. Les conférences d'EBD Group sont organisées avec le concours de sociétés leaders et d'associations commerciales internationales de premier plan et comprennent : Le service Web sophistiqué de partenariat d'EBD Group, partneringONE®, est utilisé comme moteur de partenariat lors de nombreux événements tiers dans le monde, et partnering360® est la communauté en ligne ouverte des décisionnaires dans le domaine des sciences de la vie, qui améliore les expériences de partenariat tout au long de l'année. Connectez-vous à Insight d'EBD Group pour avoir accès à toute l'actualité qui influence les stratégies commerciales dans le secteur des sciences de la vie. EBD Group est une société d'Informa. Informa est le plus grand organisateur coté en bourse d'expositions, de conférences et de formations au monde. EBD Group possède des bureaux aux États-Unis et en Europe. Pour en savoir plus, rendez-vous sur le site http://www.ebdgroup.com.


News Article | November 16, 2016
Site: www.prnewswire.co.uk

Köln, Deutschland, war letzte Woche das Zentrum für Partnerschaften zur Entwicklung von Arzneimitteln. 3.700 Führungskräfte aus der Life-Science- und Arzneimittelbranche nahmen an der globalen Live-Science-Kooperationsveranstaltung BIO-Europe® 2016 teil, die vom 7.-9. November 2016 stattfand. BIO-Europe 2016 brach im Hinblick auf die Anzahl der Delegierten und mit 20.833 geführten Einzelgesprächen ein Allzeithoch und verzeichnete gegenüber dem Jahr 2015 eine Zunahme von 9 %. Führungskräfte und Entscheidungsträger aus 1.982 Unternehmen und 63 Ländern diskutierten Asset Deals und strategische Kooperationen. Es gab 4.734 Lizenzangebote, 153 Unternehmenspräsentationen und 97 Aussteller. "Der unglaubliche Erfolg von BIO-Europe in Köln ist nicht nur ein Beleg für die Bedeutung der Region als ein zentraler europäischer Standort, sondern auch für einen soliden Biopharmasektor sowie für den verstärkten Bedarf nach Kooperation als wesentlicher Bestandteil für eine erfolgreiche strategische Planung von Unternehmen, die das gesamte Arzneimittelentwickungsspektrum abdecken", sagte Anna Chrisman, Group Managing Director der EBD Group. "Dieses Spektrum umfasst mittlerweile Jungakademiker, Startup-Unternehmen aus dem Bereich der Biotechnologie, Innovatoren in Zell- und Gentherapie und digitaler Medizin und viele andere mehr, die BIO-Europe zu einem komplett integrierten Partnering-Event machen, das für die Zukunft des Gesundheitswesens wirklich von Bedeutung ist." Während der Veranstaltung fand ein Startup-Slam-Pitching-Wettbewerb statt, der aufstrebenden Unternehmern eine Möglichkeit bot, Führungskräften aus dem Bereich Business Development, Risikokapitalanlegern und Branchenexperten ihr Unternehmen kurz vorzustellen. Die Veranstaltung, die von Johnson & Johnson Innovation mit Unterstützung von Innovation Forum und BIO.NRW gesponsert wurde, gewann Jeremy Chrisp von EpiAxis Therapeutics Pty Ltd, ein neues Startup-Unternehmen, das aus der University of Canberra in Australien heraus gegründet wurde. Sie wollen ihren neuartigen Ansatz kommerzialisieren, um das Wiederauftreten von Metastasenbildungen zu verhindern, wobei der Schwerpunkt zunächst auf Brustkrebs liegt. Die Planungen für BIO-Europe 2017 sind bereits angelaufen. Diese Veranstaltung findet vom 6.-8. November, 2017 in Berlin, Deutschland, statt und wird in Zusammenarbeit mit Berlin Partner und Berlin-Brandenburg HealthCapital durchgeführt. Als eine führende Drehscheibe für Biowissenschaften wird die deutsche Hauptstadt Biotech-Experten aus Europa und dem außereuropäischen Ausland begrüßen. In dieser Region hat vor allem der Biotechnologiesektor ein stetiges Wachstum und eine hohe Startup-Dynamik verzeichnet, wobei 90% der 240 Unternehmen des Biotech-Clusters im Bereich der Biomedizin tätig sind. Eine Stärke dieser Region ist ihre einzigartige Forschungslandschaft, die engen Verbindungen zwischen Wissenschaft und Industrie und mit über 130 Kliniken, darunter Europas größtes Universitätsklinikum, die Charité, die ausgezeichnete Infrastruktur für klinische Studien. "Als ein führender Standort für Innovation in Biotechnologie und Pharmaka freuen wir uns, dass BIO-Europe 2017 wieder nach Berlin kommt", sagte Dr. Kai Uwe Bindseil, Clustermanager für Gesundheitswirtschaft bei Berlin-Brandenburg - HealthCapital. "Über 240 Biotechnologieunternehmen arbeiten in der Hauptstadtregion täglich an der Entwicklung neuer Wirkstoffe und Diagnostika ‒ bei BIO-Europe bringen wir diese Excellenz nach vorne und schaffen die Grundlagen für neue internationale Kooperationen." Die erste Planung steht bereits, um BIO-Europe im Jahr 2018 in Zusammenarbeit mit Invest in Skåne und Copenhagen Capacity nach Kopenhagen, Dänemark, zu bringen. Kopenhagen ist für eine globale Zielgruppe ein wichtiger Biotech- und Life-Science-Standort. Das Life-Science-Cluster der Region, Medicon Valley, das Ostdänemark und Südschweden umfasst, ist auf den Gebieten Krebs, Stoffwechselerkrankungen, Entzündungen und Erkrankungen des Gehirns und des zentralen Nervensystems weltweit führend und für seine starke Patent- und Produktpipeline sowie für die einzigartige und erfolgreiche Zusammenarbeit zwischen Industrie, Akademie und Regierung in einem hohen Maße anerkannt. Schauen Sie sich die Videos von BIO-Europe und anderen wichtigen Partnering-Veranstaltungen, darunter auch Interviews mit Führungskräften und Vordenkern aus der Life-Science-Branche, auf EBD Groups Insight an, einer führende Nachrichtenquelle für die Biopharma-Branche, oder folgen Sie der Veranstaltung bei Twitter unter dem Hashtag #BIOEurope. EBD Group ist die führende Firma für Unternehmenskooperation in der globalen Life-Science-Branche. Seit 1993 nutzen Unternehmen der Biotechnologie- und Pharmabranche sowie Hersteller medizinischer Geräte die Konferenzen, Technologien und Dienstleistungen der EBD Group, um geschäftliche Potenziale zu identifizieren und strategische Partnerschaften aufzubauen, die für ihren Erfolg entscheidend sind. Unter anderem veranstaltet EBD Group mit Unterstützung von namhaften Unternehmen und internationalen Handelsverbänden die folgenden Konferenzen: EBD Groups ausgeklügelter webbasierter Kooperations-Service, partneringONE®, wird als treibende Kraft bei vielen Veranstaltungen von Dritten für Kooperationen weltweit genutzt und partnering360® ist die offene Online-Community von Entscheidungsträgern der Life-Science-Branche, die dort das ganze Jahr hindurch ihre Partnerschaften stärken können. Verpassen Sie nicht die Einblicke von EBD Group mit zeitnahen Nachrichten mit Einfluss auf die Geschäftsstrategien der Life-Science-Branche. EBD Group ist ein Unternehmen der Informa. Informa ist der weltweit größte börsennotierte Organisator von Messen, Konferenzen und Bildungsveranstaltungen. EBD Group verfügt über Büros in den USA und in Europa.


Potente M.,Max Planck Institute for Heart and Lung Research | Potente M.,International Institute of Molecular and Cell Biology | Potente M.,Berlin Partner | Makinen T.,Uppsala University
Nature Reviews Molecular Cell Biology | Year: 2017

Blood and lymphatic vessels pervade almost all body tissues and have numerous essential roles in physiology and disease. The inner lining of these networks is formed by a single layer of endothelial cells, which is specialized according to the needs of the tissue that it supplies. Whereas the general mechanisms of blood and lymphatic vessel development are being defined with increasing molecular precision, studies of the processes of endothelial specialization remain mostly descriptive. Recent insights from genetic animal models illuminate how endothelial cells interact with each other and with their tissue environment, providing paradigms for vessel type- and organ-specific endothelial differentiation. Delineating these governing principles will be crucial for understanding how tissues develop and maintain, and how their function becomes abnormal in disease. © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.


Grant
Agency: European Commission | Branch: H2020 | Program: SGA-CSA | Phase: INNOVATION | Award Amount: 279.60K | Year: 2015

Berlin Partner fr Wirtschaft und Technologie GmbH (BP) and ZAB ZukunftsAgentur Brandenburg (ZAB), the two economic and technology development agencies of Berlin and Brandenburg, both partners in the Berlin-Brandenburg Enterprise Europe Network consortium, are going to offer innovation management consultancy to SMEs with high potential for innovation, internationalization and growth. This newly developed service will allow the agencies to broaden their service portfolio to SMEs und to support existing programmes for research and innovation. While the latter usually concentrate on technologies and other outputs, InnoManage BB 2015-2016 will focus an internal management processes and capacities in the SME in order for them to successfully innovate. Target groups of InnoManage BB 2015-2016 are a) companies which have successfully applied for funding under the SME Instrument of H2020, and b) other SMEs in Berlin and Brandenburg which show the potential for innovation, internationalization and growth. As both BP and ZAB have been responsible for realizing the innovation strategies of their respective federal states since more than ten years, both agencies are fully familiar with the scope and challenges fading innovation-orientated companies. Within the frame of this project, BP and ZAB intend to carry out 71 service packages in total, BP will take over 40 service packages, ZAB 31 service packages.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: INNOSUP-1-2015 | Award Amount: 5.09M | Year: 2017

The INNOLABS project is cluster/network driven and grounded in the conviction that cluster organizations guarantee a better understanding of what kind of services and added value can be provide to their clients. Its specific focus is on unlocking the cross-sectoral collaborative potential of SMEs in combining ICT with the BIO, Health and Medicine sectors representing an emerging but still under-utilised market, and applying such results to personalized ehealth for elderly populations in both rural and urban areas. mHealth is another area within INNOLABS that will help in leveraging outstanding results. The innovations created by the combination of different value chains get to market fast and need to adapt constantly to changing end-user needs. INNOLABS will study the characteristics in market dynamics and specificities for innovations created by merging ICT and biomedical research. The main outcome of the INNOLABS project will be a catalogue of monetary and non-monetary measures provided by regional innovation clusters to support SMEs to deliver timely and innovative products and services increasing the competitiveness of the SMEs and advances the positioning of European countries in these new emerging markets. Achieving long-term sustainability will be another of INNOLABS targets. All these will be achieved by pursuing the following project objectives: 1) Test and validate optimal support measures sensitive to the specific characteristics of ICT and biomedical markets by comparing measures for traditional value chains with new fast lane measures. 2) Increase the competitiveness of SMEs by using targeted non-monetary support mechanisms that generate added value encompassing expert knowledge, new partnerships and market optimisation of products 3) Secure new funding streams to facilitate sustainable cycles of collaborative IHBM innovation by SMEs on new market platforms.


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INNOSUP | Award Amount: 78.75K | Year: 2014

Berlin Partner fr Wirtschaft und Technologie GmbH (BP) and ZukunftsAgentur Brandenburg GmbH (ZAB), the two economic and technology development agencies of Berlin and Brandenburg, both partners in the Berlin-Brandenburg Enterprise Europe Network consortium, are going to offer innovation management consultancy to SMEs with high potential for innovation, internationalization and growth. The new service will allow the agencies to broaden their service portfolio to SMEs and to support existing programmes for research and innovation. While the latter usually concentrate on technologies and other outputs, InnoManage BB will focus on internal management processes and capacities in the SME in order for them to successfully innovate. Target groups of InnoManage BB are a) companies which have successfully applied for funding in the SME instrument of H2020, and b) other SME in Berlin and Brandenburg which show the potential for innovation, internationalization and growth. As both BP and ZAB have been responsible for realizing the innovation strategies of their respective federal states since more than ten years, both agencies are fully familiar with the scope and challenges facing innovation-orientated companies. BP aims to consult 11 SME in 2014, ZAB 7.


Grant
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2013.6.6 | Award Amount: 6.23M | Year: 2013

The goal of the STREETLIFE project is the reduction of carbon emissions through a sustainable mobility concept in cities based on ICT. In particular, the aim of the project is to reduce the number of car trips by i) informing commuters about the existing transport alternatives and their real value (in terms of time, cost, carbon footprint), ii) enhancing public transport to meet the needs of the citizens and of the city, iii) promoting the usage of sustainable transports through (virtual or real) incentives.STREETLIFE will deliver a prototype urban mobility system that Integrates heterogeneous information sources both directly and indirectly related to traffic. The data sources are traffic information provided by the municipalities, data collected from vehicles and mobile devices, and data from sensors. All data is stored in one Open Data Platform that employs new approaches for capturing, storing and processing this data. Offers to the citizen safe, personalized, and real-time routing solutions covering all modes of transport to achieve the best experience during the entire travel, thanks also to advanced user interfaces Offers to the traffic management centres and city administration sophisticated ICT solutions to control the mobility resources and policies and to proactively enhance them. Establishes a new value-added chain offering an interface to mobility service providers and commercial enterprises to actively contribute to carbon reduction by proposing incentives rewarding environment friendly behaviour.The effectiveness of the solution will be proved through an in depth evaluation on three city pilots (Berlin, Tampere, and Rovereto) involving end-users. Moreover, STREETLIFE will perform an impact assessment of the solution in terms of traffic situation, end-user behaviour, and reduction of carbon emissions.


For one week, Berlin will be the international hotspot for everything relating to the Internet, the digital industry, start-ups and digital media. More than 25 international conferences, barcamps, trade shows, pitches, hackathons and forums will take place from May 4 to 10. Flagship events include: re:publica, MEDIA CONVENTION BERLIN and Heureka Conference as well as VideoDays, a pre-event being held in Berlin for the first time this year on May 1 and 2. Along with these flagship events, numerous other events will also showcase the diversity of the Berlin web scene - events like the Startup Safari, a recruiting event; Webmontag Berlin, a platform to stimulate dialogue among developers; as well as the Startupbootcamp. For an overview of all the events, please visit http://berlinwebweek.de/?lang=en. More than 18,000 visitors from around the world participated in Web Week 2014. The Berlin Web Week is a project by the Senate Department for Economics, Technology and Research and Berlin Partner for Business and Technology. re:publica is Europe's leading event for the digital society. Since 2007, it has developed into a "community-wide conference" with 6,000 participants. For #rp15, 450 speakers from 45 countries are expected for more than 300 hours of events on 16 stages. re:publica has expanded by partnering with MEDIA CONVENTION Berlin. Subconferences such as Global Innovation Gathering (GIG), City of the Future, #FASHIONTECH BERLIN and re:cord MusicDay will focus on specific themes. http://re-publica.de/en/press-0 This year, MEDIA CONVENTION Berlin will be presenting itself in an even more international, innovative and multi-faceted light. In cooperation with Medienanstalt Berlin-Brandenburg and re:publica, numerous events relating to film, television, platforms, digitization, regulation and new journalism formats are set to take place on three stages on May 5 and 6. http://mediaconventionberlin.com/en After the success of last three HEUREKA conferences, this one-day event, which will be held on May 5, 2015, will include distinguished speakers, interactive workshops and start-up pitches in the fourth round. HEUREKA Conference has set itself the task of taking young companies to the next level. In addition, the event will provide information on key factors for sustained success, encourage networking with entrepreneurs and facilitate exchanges with powerful investors and media representatives. http://heureka-conference.com/home For the first time ever, VideoDays will also take place in Berlin this year, on May 1 and 2. It is the largest YouTube meeting in Europe and the largest YouTube show in the world. On May 1, CommunityDay, fans will have the opportunity to meet famous YouTube stars. On May 2, ShowDay, there will be a live show during which many famous YouTube acts will take the stage. On this occasion, the popular PlayAwards will also be awarded in Berlin to the most successful YouTube channels. Up to 6,500 visitors are expected in the Arena Berlin. http://videodays.eu/

Loading Berlin Partner collaborators
Loading Berlin Partner collaborators